{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:22:37Z","timestamp":1791084157764,"version":"4.1.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00329","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:12:09Z","timestamp":1585699929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":125,"title":["Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review"],"prefix":"10.3389","volume":"11","author":[{"given":"Abu Saleh Mohammad","family":"Mosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Mosharraf","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau James","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Illhoi","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"B1","first-page":"S259","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","volume":"23","author":"Adel","year":"2017","journal-title":"Am. J. Manage. Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12482","article-title":"Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan","volume":"30","author":"Baba","year":"2016","journal-title":"Dis. Esophagus."},{"key":"B3","first-page":"374","article-title":"Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study","volume":"5","author":"Booth","year":"2007","journal-title":"J. Support. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.3747\/co.19.1074","article-title":"Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting","volume":"19","author":"Bouganim","year":"2012","journal-title":"Curr. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.suponc.2011.10.007","article-title":"Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy","volume":"10","author":"Bourdeanu","year":"2012","journal-title":"J. Support. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.suponc.2011.06.007","article-title":"Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial","volume":"10","author":"Celio","year":"2012","journal-title":"J. Support. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00520-012-1558-9","article-title":"Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline\/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase I","volume":"21","author":"Celio","year":"2013","journal-title":"Support. Care Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/NNR.0b013e3182691438","article-title":"Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy","volume":"61","author":"Chan","year":"2012","journal-title":"Nurs. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Support. Care Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/cncr.23594","article-title":"How do patient expectancies, quality of life, and postchemotherapy nausea interrelate","volume":"113","author":"Colagiuri","year":"2008","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1097\/NCC.0000000000000342","article-title":"Chemotherapy-Induced Nausea and Vomiting in Women With Gynecological Cancer: A Preliminary Single-Center Study Investigating Medical and Psychosocial Risk Factors","volume":"39","author":"Di Mattei","year":"2016","journal-title":"Cancer Nurs."},{"key":"B13","first-page":"W1","article-title":"Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. I. Acute nausea and vomiting","volume":"7","author":"Dranitsaris","year":"2009","journal-title":"J. Support Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.suponc.2012.05.001","article-title":"Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting","volume":"11","author":"Dranitsaris","year":"2013","journal-title":"J. Support. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc Med. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0959-8049(05)80075-9","article-title":"Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron","volume":"28","author":"du Bois","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JOP.2010.000151","article-title":"Prevalence of Delayed Nausea and\/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer","volume":"8","author":"Fleishman","year":"2012","journal-title":"J. Oncol. Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.21873\/anticanres.12144","article-title":"Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy","volume":"37","author":"Fujii","year":"2017","journal-title":"Anticancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00404-013-3058-7","article-title":"Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin","volume":"289","author":"Furukawa","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","article-title":"Chemotherapy-induced nausea and vomiting in routine practice: a European perspective","volume":"12","author":"Glaus","year":"2004","journal-title":"Support. Care Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","article-title":"Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population","volume":"19","author":"Haiderali","year":"2011","journal-title":"Support. Care Cancer"},{"key":"B22","first-page":"1523","article-title":"Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race","volume":"11","author":"Hassan","year":"2010","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1188\/09.CJON.54-64","article-title":"Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes","volume":"13","author":"Hawkins","year":"2009","journal-title":"Clin. J. Oncol. Nurs."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00520-017-3679-7","article-title":"A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting","volume":"25","author":"Hayashi","year":"2017","journal-title":"Support. Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.2147\/CMAR.S176574","article-title":"Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study","volume":"10","author":"Hayashi","year":"2018","journal-title":"Cancer Manage. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support. Care Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1007\/s00520-012-1402-2","article-title":"Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting","volume":"20","author":"Higa","year":"2012","journal-title":"Support. Care Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","article-title":"Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study","volume":"20","author":"Hilarius","year":"2012","journal-title":"Support. Care Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002476","article-title":"Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly\/Moderately Emetogenic Chemotherapy","volume":"95","author":"Hu","year":"2016","journal-title":"Med. (Baltimore)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/bjc.1996.499","article-title":"Impact of tumour burden on chemotherapy-induced nausea and vomiting","volume":"74","author":"Hursti","year":"1996","journal-title":"Br. J. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-015-0908-2","article-title":"Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy","volume":"21","author":"Iihara","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1089\/jpm.2011.0058","article-title":"Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy","volume":"14","author":"Jones","year":"2011","journal-title":"J. Palliat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","article-title":"International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice","volume":"722","author":"Jordan","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3238\/arztebl.2017.0481","article-title":"Supportive Treatments for Patients with Cancer","volume":"114","author":"Jordan","year":"2017","journal-title":"Dtsch. Arztebl. Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.clinthera.2018.10.004","article-title":"Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study","volume":"40","author":"Kawazoe","year":"2018","journal-title":"Clin. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00520-014-2339-4","article-title":"Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy","volume":"23","author":"Kitazaki","year":"2015","journal-title":"Support. Care Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/07420528.2017.1295978","article-title":"Late chronotypes are associated with neoadjuvant chemotherapy-induced nausea and vomiting in women with breast cancer","volume":"34","author":"Lee","year":"2017","journal-title":"Chronobiol. Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00000421-200302000-00003","article-title":"Reduced maintenance of complete protection from emesis for women during chemotherapy cycles","volume":"26","author":"Liaw","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ygyno.2015.12.029","article-title":"A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan","volume":"140","author":"Mizuno","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support. Care Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s00520-013-1843-2","article-title":"Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting","volume":"21","author":"Molassiotis","year":"2013","journal-title":"Support. Care Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: Results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J. Pain Symptom Manage."},{"key":"B44","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jpainsymman.2015.12.317","article-title":"Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study","volume":"51","author":"Molassiotis","year":"2016","journal-title":"J. Pain Symptom Manage."},{"key":"B45","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00520-013-2046-6","article-title":"Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer","volume":"22","author":"Murakami","year":"2014","journal-title":"Support. Care Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/21548331.2015.1077095","article-title":"Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis","volume":"43","author":"Natale","year":"2015","journal-title":"Hosp. Pract. (1995)."},{"key":"B47","doi-asserted-by":"publisher","first-page":"877","DOI":"10.21873\/anticanres.12297","article-title":"Control of Nausea and Vomiting in Patients Receiving Anthracycline\/Cyclophosphamide Chemotherapy for Breast Cancer","volume":"38","author":"Nawa-Nishigaki","year":"2018","journal-title":"Anticancer Res."},{"key":"B48","unstructured":"Clinical Practice Guidelines in Oncology: Antiemesis, Version 2.2015\n          National Comprehensive Cancer Network2015"},{"key":"B49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group","volume":"15","author":"Osoba","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"B50","first-page":"W9","article-title":"Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool. II. Delayed nausea and vomiting","volume":"7","author":"Petrella","year":"2009","journal-title":"J. Support Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R","article-title":"Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model","volume":"64","author":"Pollera","year":"1989","journal-title":"Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1007\/s00520-016-3146-x","article-title":"Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients","volume":"24","author":"Rha","year":"2016","journal-title":"Support. Care Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1002\/cncr.20718","article-title":"Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma","volume":"101","author":"Roscoe","year":"2004","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-009-0723-2","article-title":"Insight in the prediction of chemotherapy-induced nausea","volume":"18","author":"Roscoe","year":"2010","journal-title":"Support. Care Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1345\/aph.1L437","article-title":"Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide","volume":"43","author":"Shih","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.21873\/anticanres.13101","article-title":"Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy","volume":"39","author":"Shimokawa","year":"2019","journal-title":"Anticancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/pgs.14.168","article-title":"Pharmacogenetics of chemotherapy-induced nausea and vomiting","volume":"16","author":"Sugino","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","article-title":"Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer","volume":"13","author":"Sun","year":"2005","journal-title":"Support. Care Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","article-title":"Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea","volume":"22","author":"Takemoto","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","article-title":"Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan","volume":"18","author":"Tsuji","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial","volume":"27","author":"Tsuji","year":"2019","journal-title":"Support. Care Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1248\/bpb.b17-00318","article-title":"Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP","volume":"40","author":"Uchida","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"B65","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support. Care Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","article-title":"Prognostic factors for chemotherapy induced nausea and vomiting","volume":"722","author":"Warr","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/JCP.0b013e31824888a1","article-title":"Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting","volume":"32","author":"Yap","year":"2012","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:12:13Z","timestamp":1585699933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":67,"alternative-id":["10.3389\/fphar.2020.00329"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00329","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"article-number":"329"}}